DCGI approved Kokate panel’s procedure for subsequent applicants for FDCs

  • News
  • June 30, 2017

New Delhi: Kokate Committee’s rational, a set of procedures has been approved and issued for subsequently fixed dose combinations (FDCs) applicants by The Drugs Controller General India (DCGI).

DCGI also released notice to instruct applicants to submit the application with relevant information and mention “Not applicable” for non-applicable boxes mentioned in Form 44.

Manufacturers, who have holding approved licenses from SLA (State Licensing Authority) needs to submit the documents; duly filled, signed and stamped Form 44; Rs. 15,000 duly signed treasury challan by Bank of Baroda; Composition and name of the FDC; product permission issued by SLA and copy of manufacturing license in Form 25/28; FDCs permitted for continued manufacturing & marketing under 18 months policy decision; SI No. of the FDC as per the list available on website, and name of FDC.

The notice clearly mentioned that 4 months of the time given to the manufacturers with valid SLA for such FDCs but not have approved NOC have to submit their applications to the Directorate as soon as possible within 4 months and if they fail then the license will be considered as without legal validity.

Stakeholders requested DCGI to specify the number of the minimum documents required.

  • Related Posts

    Centre Pushes Haryana to Fast-Track AIIMS Rewari

    New Delhi | August 18, 2025 — The Union government has urged Haryana to speed up work on AIIMS Rewari (Majra) and resolve on-ground hurdles so the institute can open…

    Rajasthan Drops 1,114 Hospitals From RGHS in Fraud Drive

    Jaipur, August 18, 2025 — Rajasthan has removed 1,114 private hospitals from the Rajasthan Government Health Scheme (RGHS) after a statewide fraud sweep. The Health Department also suspended 1,901 healthcare…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Delhi HC allows Zydus to sell biosimilar of blockbuster anti-cancer drug Nivolumab

    Delhi HC allows Zydus to sell biosimilar of blockbuster anti-cancer drug Nivolumab

    DoP may exempt 11 more drugs from public procurement rules

    DoP may exempt 11 more drugs from public procurement rules

    DoP calls for proposals to set up common facilities for medical device clusters

    DoP calls for proposals to set up common facilities for medical device clusters

    TN Information Commission raps petitioner for abusing RTI Act with excessive requests

    TN Information Commission raps petitioner for abusing RTI Act with excessive requests

    Granules India gets USFDA tentative nod for generic ADHD treatment tablets

    Granules India gets USFDA tentative nod for generic ADHD treatment tablets

    Polymatech begins domestic manufacturing of vein finder devices

    Polymatech begins domestic manufacturing of vein finder devices